Home › Acute Myeloid Leukemia › Arkansas
Acute Myeloid Leukemia clinical trials in Arkansas
12 studies for Acute Myeloid Leukemia are looking for participants at sites in Arkansas.
Cities in Arkansas
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT05554406Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Fort Smith, Fort Smith
- CARTI Cancer Center, Little Rock
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Arkansas at Little Rock, Little Rock
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Arkansas for Medical Sciences, Little Rock
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Oct 28, 2026 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06672146A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Arkansas Children's Hospital, Little Rock
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Arkansas Children's Hospital, Little Rock
RecruitingPhase 3
Ages 1 to 25 · All sexes · Updated Sep 4, 2026 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Arkansas Children's Hospital, Little Rock
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Arkansas Children's Hospital, Little Rock
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Arkansas Children's Hospital, Little Rock
RecruitingPhase 1
Up to age 21 · All sexes · Updated Apr 22, 2026 · NCT05101551From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.